Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
27/05/2026 07:35
BRIEF-Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia May 27 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says in a statement on the Budapest Stock Exchange:
AGREES WITH ACRUX ON EXTENSION OF ITS LICENSE AGREEMENT DATED 2013 RELATING TO TRANSDERMAL ESTRADIOL SPRAY LENZETTO TO AUSTRALIAN MARKET
AMENDED AGREEMENT PROVIDES RICHTER EXCLUSIVE COMMERCIALIZATION RIGHTS FOR THE AUSTRALIAN MARKET
RICHTER SAYS ACRUX WILL RECEIVE TOTAL PAYMENTS OF AUD 5.4 MILLION OVER THE COMING PERIOD
Source text: [ID:]
Further company coverage: GDRB.BU
(Reporting by Krisztina Than)
((Krisztina.Than@thomsonreuters.com;))
Recent news on Acrux
See all newsBrief: Acrux Licenses Lenzetto For Australian Market For A$5.4 Million
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Acrux Says Capital Gains Tax Exemptions Remain In Place For Acrux
Australia's Acrux jumps on placement to fund female testosterone program
Brief: Acrux Raises A$1.6 Mln Via At 0.95 AU Cents Per Share